Good news! Almost a miracle! Unfortunately, only one patient so far.
"... Now, early results from a phase I clinical trial suggest that replacing those lost insulin-producing cells with new ones could be a viable treatment. The first patient to receive this kind of transplant has now been insulin-independent for over a year, the team says. ...
For the trial, the scientists isolated stem cells from her adipose tissue, and induced them to return to an earlier state of development, from which they could differentiate into almost any cell type. Then, they were coaxed to become pancreatic islet cells, which were cultivated and transplanted into her abdominal muscles. ...
Other studies have been done before with similar promising results, but this new trial differs in a few key ways. For one, the stem cells are induced chemically rather than genetically, and come from a different source within the patient’s body. ..."
From the highlights and abstract:
"Highlights
• Patient-derived islets were generated with chemically induced pluripotent stem cells
• Transplantation of these islets to an abdominal site led to engraftment in one patient
• Exogenous insulin-independent glycemic control was restored in the patient
• All safety and efficacy clinical endpoints were met at 1-year follow-up of the patient
Summary
We report the 1-year results from one patient as the preliminary analysis of a first-in-human phase I clinical trial ... assessing the feasibility of autologous transplantation of chemically induced pluripotent stem-cell-derived islets (CiPSC islets) beneath the abdominal anterior rectus sheath for type 1 diabetes treatment. The patient achieved sustained insulin independence starting 75 days post-transplantation. The patient’s time-in-target glycemic range increased from a baseline value of 43.18% to 96.21% by month 4 post-transplantation, accompanied by a decrease in glycated hemoglobin, an indicator of long-term systemic glucose levels at a non-diabetic level. Thereafter, the patient presented a state of stable glycemic control, with time-in-target glycemic range at >98% and glycated hemoglobin at around 5%. At 1 year, the clinical data met all study endpoints with no indication of transplant-related abnormalities. Promising results from this patient suggest that further clinical studies assessing CiPSC-islet transplantation in type 1 diabetes are warranted."
NKU Research Team Publishes Breakthrough in Type 1 Diabetes Treatment in Cell (original news release)
Graphical abstract
No comments:
Post a Comment